| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
As an amino acid derivative, Fmoc-Phe(CF2PO3)-OH does not have a defined primary drug target in the context of therapeutic development. However, as a phosphonodifluoromethylphenylalanine analogue, it is used in research to study phosphotyrosine-mediated signaling pathways and protein-protein interactions. The phosphonodifluoromethyl group is a hydrolytically stable mimic of phosphotyrosine, which is a key post-translational modification involved in cell signaling. The compound is widely applied in pharmaceutical drug synthesis, specifically targeting a range of ailments such as cancer and autoimmune disorders. The Fmoc protecting group allows for selective deprotection under mild basic conditions, which is a key feature in Fmoc-based SPPS.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies on amino acid derivatives, including this phosphonodifluoromethylphenylalanine analogue, have demonstrated their capacity to influence the release of anabolic hormones, modulate fuel availability for cellular activity, enhance mental performance under stress-related conditions, and prevent exercise-induced muscle damage. As a phosphotyrosine analog, this compound may be used in cell-based assays to investigate tyrosine phosphorylation signaling, protein-protein interactions, and the effects of phosphatase-resistant phosphotyrosine mimics on cellular signaling pathways. The compound can also be utilized in studies examining the role of phosphotyrosine in cancer and autoimmune disorders. |
| ln Vivo |
In vivo studies on amino acid derivatives have shown that they affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. As a protected phosphonodifluoromethylphenylalanine derivative, this compound may be administered in animal studies to evaluate the effects of phosphatase-resistant phosphotyrosine analogs on biological systems. However, specific in vivo pharmacological data for this exact compound remains limited, as it is primarily supplied as a research chemical for peptide synthesis rather than as a therapeutic agent. The Fmoc group would likely be cleaved in vivo to release the active phosphonodifluoromethylphenylalanine.
|
| Enzyme Assay |
Non-cell-based enzyme or receptor binding assays for this compound typically involve studies with purified enzymes such as protein tyrosine phosphatases (PTPs) or SH2 domain-containing proteins to evaluate the effects of phosphonodifluoromethyl substitution on binding affinity and enzymatic activity. Standard protocols include incubating varying concentrations of the test compound with the enzyme or protein source in appropriate buffer systems, followed by measurement of binding or activity using spectrophotometric, fluorometric, or surface plasmon resonance (SPR) methods. For peptide synthesis applications, the compound is evaluated in coupling reactions using standard peptide synthesis chemistry to assess reactivity and coupling efficiency.
|
| Cell Assay |
Cell-based assays for this phosphonodifluoromethylphenylalanine derivative typically utilize cancer cell lines or other cell types to evaluate compound effects on cell signaling, proliferation, and survival. Standard protocols involve culturing cells in appropriate media at 37°C in 5% CO₂, followed by treatment with varying concentrations of the compound or peptides containing it (typically 0.1-100 μM) for 24-72 hours. Cell viability is assessed using MTT or CCK-8 assays. The compound's effects on tyrosine phosphorylation signaling can be studied using Western blotting with phosphotyrosine-specific antibodies, or using reporter gene assays. For peptide synthesis applications, the compound is used as a building block in Fmoc-based SPPS.
|
| Animal Protocol |
In vivo animal studies for phosphonodifluoromethylphenylalanine-containing peptides typically involve administration via oral gavage, intraperitoneal injection, or intravenous injection in rodent models (mice or rats). Standard protocols include dosing at ranges of 1-50 mg/kg body weight, with observations over 1-14 days depending on the study objectives. For studies evaluating the effects of phosphotyrosine analog-containing peptides on cancer or autoimmune disorders, xenograft or disease models may be employed. Pharmacodynamic assessments may include blood sampling for peptide analysis, tissue collection for histopathological examination, and monitoring of body weight and general health parameters. All animal studies must comply with institutional ethical guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for this Fmoc-protected phosphonodifluoromethylphenylalanine derivative can be inferred from structurally related compounds. As a medium-sized molecule (molecular weight 517.42 g/mol), it is expected to have moderate bioavailability. The Fmoc protecting group is likely to be cleaved in vivo to release the active phosphonodifluoromethylphenylalanine. The compound shows good solubility in DMSO (90 mg/mL). For in vivo administration, formulations using suitable co-solvent systems may be employed. The compound should be stored as powder at -20°C for long-term preservation (3 years) or at 4°C for 2 years. Definitive PK parameters such as half-life, Cmax, and AUC require formal studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for this specific compound are limited as it is supplied for research use only and not intended for human therapeutic applications. Phosphonodifluoromethyl compounds may have specific toxicity profiles related to their phosphonate and fluorine content. Appropriate safety precautions should be observed during handling, including the use of personal protective equipment and work in well-ventilated areas. The compound may cause skin and eye irritation upon contact. Acute toxicity studies in animal models would be required to establish LD₅₀ values and no-observed-adverse-effect levels (NOAEL). For in vitro cytotoxicity assessment, the compound can be tested in mammalian cell lines using standard MTT or LDH release assays.
|
| References | |
| Additional Infomation |
Fmoc-Phe(CF2PO3)-OH is a phenylalanine analogue featuring a phosphonodifluoromethyl group on the phenyl ring. The compound is a building block for the introduction by Fmoc SPPS of the hydrolytically stable phosphotyrosine analog phosphonodifluoromethylphenylalanine (F2Pmp). The pKa of F2Pmp more closely resembles that of a phosphate group, making it a better analog than phosphonomethylphenylalanine. It is widely applied in pharmaceutical drug synthesis, specifically targeting cancer and autoimmune disorders. It is not an approved drug and has not undergone clinical trials; it is strictly for research purposes.
|
| Molecular Formula |
C25H22F2NO7P
|
|---|---|
| Molecular Weight |
517.42
|
| Exact Mass |
517.11
|
| CAS # |
160751-44-0
|
| PubChem CID |
11763031
|
| Appearance |
Pink to orange solid powder
|
| Density |
1.32g/cm3
|
| Boiling Point |
721.4ºC at 760mmHg
|
| Flash Point |
390.1ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.568
|
| LogP |
4.838
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
36
|
| Complexity |
822
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
OC(=O)[C@H](CC1=CC=C(C=C1)C(F)(F)P(O)(O)=O)NC(=O)OCC2C3=C(C=CC=C3)C4=C2C=CC=C4
|
| InChi Key |
XKWYQNFAGUNPJV-QFIPXVFZSA-N
|
| InChi Code |
InChI=1S/C25H22F2NO7P/c26-25(27,36(32,33)34)16-11-9-15(10-12-16)13-22(23(29)30)28-24(31)35-14-21-19-7-3-1-5-17(19)18-6-2-4-8-20(18)21/h1-12,21-22H,13-14H2,(H,28,31)(H,29,30)(H2,32,33,34)/t22-/m0/s1
|
| Chemical Name |
(2S)-3-[4-[difluoro(phosphono)methyl]phenyl]-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (193.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9327 mL | 9.6633 mL | 19.3267 mL | |
| 5 mM | 0.3865 mL | 1.9327 mL | 3.8653 mL | |
| 10 mM | 0.1933 mL | 0.9663 mL | 1.9327 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
